News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|March 13, 2025

Recapping the Evolving Treatment Landscape for Atopic Dermatitis

Author(s)Naiem Issa, MD, PhD, FAAD

The panelist discusses how the therapeutic options for atopic dermatitis have expanded significantly with the emergence of targeted biologics, oral agents, and refined topical treatments, transforming the management approach for patients across the disease spectrum.

Episodes in this series

1 expert is featured in this series.

EP. 1 Recognizing Atopic Dermatitis Heterogeneity and Tailoring Treatment

1 expert is featured in this series.

EP. 2 Navigating Pediatric Treatment Options for a 10-Year-Old Girl

1 expert is featured in this series.

EP. 3 Discussing Efficacy and Safety of Dupilumab With Patients and Caregivers

1 expert is featured in this series.

EP. 4 Tackling Topical Treatments for a 24-Year-Old Man With Mild Atopic Dermatitis

1 expert is featured in this series.

EP. 5 Switching Biologic Therapies in a 32-Year-Old Woman With Severe Atopic Dermatitis

1 expert is featured in this series.

EP. 6 Oral Treatment Options for a 36-Year-Old Man With Prior Systemic Corticosteroid Use

1 expert is featured in this series.

EP. 7 Recapping the Evolving Treatment Landscape for Atopic Dermatitis

EP. 8 Using Real-World AD Cases to Pick the Right Therapy for Each Patient

EP. 8 Using Real-World AD Cases to Pick the Right Therapy for Each Patient

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Clinical Pearls for Management of Pediatric Atopic Dermatitis With Topicals

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Therapy Gaps in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Counseling Caregivers in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Escalating to Systemic Therapies in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Treatment Adherence in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 7th 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Transformative Advances This Year and Beyond

FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol

Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control

"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions

Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO

© 2025 MJH Life Sciences^®

All rights reserved.